Zoledronic acid injection (Aclasta) prevention of osteoporosis in clinical studies in patients with total knee replacement bone loss in the early postoperative

Trial Profile

Zoledronic acid injection (Aclasta) prevention of osteoporosis in clinical studies in patients with total knee replacement bone loss in the early postoperative

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2016 Status changed from not yet recruiting to completed.
    • 18 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top